The mission of the UF Health Cancer Center Clinical Trials Office (CTO) is to help deliver new and promising cancer treatments that improve the lives of our patients at the UF Health Cancer Center. The CTO provides support to our clinical investigators for the development and implementation of cancer clinical trials — facilitating the conduct of high-quality clinical research while adhering to the highest ethical standards and maintaining compliance with all governing bodies. This program will continue to undergo significant expansion over the next few years, as part of the initiative to become a National Cancer Institute-designated cancer center.
Currently, our clinical research program consists of the CTO and 11 disease-specific working groups (e.g., thoracic, GI, GU, neuro-oncology, hematologic malignancies). It also supports an Experimental Therapeutics Incubator for early-phase clinical trials that may have patient eligibility across several cancer types. Additionally, the Clinical Trials Office provides clinical trial support for outside institutions with affiliations through UF Health, the university’s academic health center.
The UF Health Cancer Center joined the National Cancer Institute’s Experimental Therapeutics Clinical Trial Network, or ETCTN, in December 2017 under the leadership of the University of Pittsburgh Cancer Institute.
As a member of the network, the UF Health Cancer Center can give patients access to early phase experimental therapeutic clinical trials — research studies that assess new treatments for efficacy and safety. Such novel treatments are developed by scientists across the NCI’s network of centers and conducted at ETCTN locations.
Membership in the ETCTN provides UF Health Cancer Center researchers and clinicians funding to conduct these investigations and a platform to present their ideas for the development of new treatments as clinical trials — while allowing collaboration with other leading cancer centers.
“We anticipate having the first set of these trials to offer to patients in early spring 2018,” said Thomas George, M.D., the associate director for clinical investigations at the Cancer Center.